This study by Brekelmans et al. (Thromb Haemost, 2017) aimed to analyze the characteristics of abnormal vaginal bleeding in patients being treated for venous thromboembolism (VTE) with either apixaban or enoxaparin / warfarin.
Retrospective Cohort Study
Using data from the AMPLIFY trial, incidence of abnormal vaginal bleeding was compared between women taking apixaban and enoxaparin/warfarin in the setting of VTE. 1,122 women were treated with apixaban and 1,106 were treated with enoxaparin/warfarin. Clinically relevant non-major vaginal bleeding occurred in 2.5% apixaban and 2.1% enoxaparin/warfarin recipients (odds ratio 1.2, 95 % CI 0.7-2.0). 45% of apixaban and 20% of enoxaparin/warfarin bleeds were vaginal in origin. In premenopausal patients, bleeding tended to be more prolonged for those in the apixaban group. Overall, diagnostic tests were performed in 21% of apixaban and 29% of enoxaparin/warfarin patients. Following diagnostic tests, medical treatment was not necessary in 57% of apixaban and 67% of enoxaparin/warfarin patients. The authors concluded that while the relative occurrence of bleeding was somewhat higher in women treated with apixaban (with odds ratio 95% CI crossing ‘1’), in most patients (75%) the overall clinical presentation and course were mild and comparable between groups.
Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin
Please log in to access OBGFirst and the 2T Ultrasound Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
